Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVX #200
- Development stage
- Preclinical
- Lead developer
- MalarVx
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intra Cisterna Magna
01
Overview
MVX #200 is an investigational self-replicating RNA (repRNA) vaccine candidate developed by MalarVx for the prevention of malaria. The vaccine utilizes a proprietary Lipid Inorganic Nanoparticle (LION) delivery system to transport repRNA encoding malaria-specific antigens into host cells. Unlike conventional mRNA vaccines, repRNA contains genetic machinery that allows it to self-amplify once inside the cell, potentially leading to higher and more sustained antigen expression. This mechanism is intended to elicit a robust and durable immune response, including both antibody and T-cell activity, while potentially requiring lower doses than standard RNA platforms. MVX #200 is currently in the IND-enabling stage of development.
- Other names
- MVX-MalarVx-repRNA (self-replicating RNA)-MalariaMVX-MalarVx-repRNArepRNA malaria vaccine
Beyond the preview
Go deeper on MVX #200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVX #200.